Pierre Attali

QuantifiCare SA provides medical image processing tools and services. The company offers its services to pharmaceutical and biotechnology companies, medical device manufacturers, diagnosis and research companies, radiopharmaceutical companies and research institutions. QuantifiCare was founded in February 2001 and is headquartered in Valbonne, France.

ORPHELIA Pharma SA specializes on biopharmaceutical products improving the health and well being of severely disabled children. The company was founded by Hugues Bienaymé in 2007 and is headquartered in Paris, France.

Urogene is a urology-focused biopharmaceutical company engaged in the development of small molecule drugs for the treatment of: Lower Urinary Tract Dysfunctions such as overactive bladder and stress urinary incontinence, Prostate and Bladder Cancers. They have the expertise to set-up and manage preclinical and clinical development plans in these therapeutic areas. Its objective is to provide innovative candidates with clinical proof-of-concept of efficacy and safety. Partnerships with key players in the urology field will be proposed for late-stage clinical development and commercialization. Besipirdine, in-licensed from Aventis, is now reaching that stage. It is a potential novel first-in-class oral treatment for Overactive Bladder (OAB) currently in Phase II development. Development is planned in additional indications including Interstitial Cystitis (IC) and Stress-related Urinary Incontinence (SUI). Besipirdine represents a potential breakthrough and novel blockbuster product in OAB, SUI, mixed incontinence and IC.

Synthelabo was a pharmaceutical company which was focused on cardiovascular disease/thrombosis, disorders of central nervous system, oncology and internal medicine. The company was headquartered in Le Plessis-Robinson, France.

Anceris SA specializes in developing therapeutic products for treatment of cancer. The company was founded in February 2000 and is headquartered in Paris, France.